Peginterferon Alpha-2a
ApprovedSmall molecule
Johnson & JohnsonPeginterferon Alpha-2a is one of 87 small molecule programs targeting Portal Hypertension. It is currently in Approved.
3
Indications
12
Total Trials
0
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Peginterferon Alpha-2a
Johnson & JohnsonApproved
PEG-Intron
Merck & Co.Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
SOF/VEL
GileadPreclinical
Keyhole-Limpet Hemocyanin
Bristol-Myers SquibbPreclinical
Pegintron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis6 trials
Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues
Unknown status·—·Phase 4·NCT02362490·200 enrolled
Show 3 more trials
Pegylated Interferon to Treat Chronic Hepatitis D
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00023322·13 enrolled
Hepatitis C3 trials
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00122616·52 enrolled
Portal Hypertension1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peginterferon Alpha-2a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company